Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1042 and Radiotherapy With or Without Pembrolizumab in Metastatic Solid Tumors
NCT05491317Phase 2Terminated
- Sponsor
- Genmab
- Start
- Mar 2023
- Primary completion
- Aug 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tecaginlimab in solid tumor (2 arms), sponsored by Genmab. Primary endpoint: Dose Limiting Toxicities at 21 days. Started Mar 2023; status: terminated.
02
Drugs
tecaginlimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05491317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491317.